Biliary tract cancers include cancers of the gallbladder, ampulla of Vater, and bile ducts. About 3% of gastrointestinal malignancies are caused by this uncommon cancer. It is categorized as gallbladder and ampullary malignancies, as well as intrahepatic, helar, and extrahepatic cholangiocarcinomas. Chronic inflammation, primary sclerosing cholangitis, and liver fluke infections are risk factors. Biliary tract cancers is frequently discovered at advanced stages and is becoming more common worldwide in some areas. The biliary tract cancers pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the biliary tract cancers pipeline analysis include Merck Sharp & Dohme LLC, Eli Lilly and Company, and Boehringer Ingelheim, among others.
Leading drugs currently in the pipeline include pembrolizumab, ramucirumab, and others.
Advancements in novel antiviral therapies and immune-modulating agents are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Biliary Tract Cancers Pipeline Analysis Report by Expert Market Research gives comprehensive insights into biliary tract cancers therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for biliary tract cancers. The biliary tract cancers report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The biliary tract cancers pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with biliary tract cancers treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to biliary tract cancers.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Biliary tract cancers are an uncommon class of cancers that involve the gallbladder and bile ducts. It includes malignancies of the gallbladder, ampulla of Vater, intrahepatic, and extrahepatic regions.
The kind and stage of biliary tract carcinoma determines how it is treated. The sole treatment for localized BTC is surgery, though liver transplantation may be an option in certain circumstances. Chemotherapy, usually gemcitabine-cisplatin, is used to treat advanced BTC. Immunotherapy, such as durvalumab or pembrolizumab, is frequently used in conjunction with chemotherapy. For mutations, targeted treatments such as FGFR2 and IDH1 inhibitors are employed. Stent placement, photodynamic therapy, and locoregional treatments are examples of palliative strategies.
Biliary tract cancers are uncommon and varies greatly by region. Each year, about 8,000 cases of intrahepatic and extrahepatic bile duct malignancies are detected in the United States. Southeast Asia has a greater prevalence of liver fluke infections worldwide. Older people are impacted most often.
This section of the report covers the analysis of biliary tract cancers drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total biliary tract cancers clinical trials.
In the biliary tract cancers pipeline, most candidates are in Phase II with 60% of the projects, followed by 20% in Phase I and 20% in Phase III demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
The drug molecule categories covered under the biliary tract cancers pipeline analysis include Monoclonal antibody, Peptides and Small molecule. The biliary tract cancers report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for biliary tract cancers.
Capsid assembly modulators (CAMs) are emerging as promising agents in the biliary tract cancers pipeline. For example, HAP18, a small molecule assembly agonist, disrupts the HBV core protein dimer’s hydrogen bonding while stabilizing capsids. This dual action results in empty, defective capsids and impedes viral genome release, reducing the formation of new infectious particles.
The EMR report for the biliary tract cancers pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in biliary tract cancers clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for biliary tract cancers. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of biliary tract cancers drug candidates.
Pembrolizumab, developed by Merck Sharp & Dohme LLC, is in Phase 3 of a clinical trial for treating biliary tract cancer. The trial evaluates its safety and efficacy, particularly in combination with chemotherapy, aiming to improve progression-free and overall survival. Pembrolizumab is an anti-PD-1 monoclonal antibody that boosts the immune system's ability to detect and fight cancer cells.
Eli Lilly and Company's Ramucirumab is undergoing Phase 2 of a clinical trial to treat biliary tract cancer. The goal of the experiment is to increase overall survival and progression-free survival by assessing its safety and effectiveness, especially when combined with chemotherapy. Ramucirumab is a monoclonal antibody that inhibits VEGFR-2, preventing the development of blood vessels that supply tumors with nutrients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Biliary Tract Cancers Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for biliary tract cancers. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into biliary tract cancers collaborations, regulatory environments, and potential growth opportunities.
Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share